KR101880716B1 - 리스페리돈 또는 팔리페리돈 임플란트 제형 - Google Patents

리스페리돈 또는 팔리페리돈 임플란트 제형 Download PDF

Info

Publication number
KR101880716B1
KR101880716B1 KR1020147035300A KR20147035300A KR101880716B1 KR 101880716 B1 KR101880716 B1 KR 101880716B1 KR 1020147035300 A KR1020147035300 A KR 1020147035300A KR 20147035300 A KR20147035300 A KR 20147035300A KR 101880716 B1 KR101880716 B1 KR 101880716B1
Authority
KR
South Korea
Prior art keywords
risperidone
molecular weight
polymer
days
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147035300A
Other languages
English (en)
Korean (ko)
Other versions
KR20150016964A (ko
Inventor
아두리스 이본 구티에로
로드리게스 기예르모 프랑코
Original Assignee
라보라토리오스 파마슈티코스 로비, 에스.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101880716(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 라보라토리오스 파마슈티코스 로비, 에스.아. filed Critical 라보라토리오스 파마슈티코스 로비, 에스.아.
Publication of KR20150016964A publication Critical patent/KR20150016964A/ko
Application granted granted Critical
Publication of KR101880716B1 publication Critical patent/KR101880716B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147035300A 2012-05-31 2013-05-31 리스페리돈 또는 팔리페리돈 임플란트 제형 Active KR101880716B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170362.3A EP2529756B1 (en) 2011-05-31 2012-05-31 Risperidone and/or Paliperidone implant formulation
EP12170362.3 2012-05-31
PCT/EP2013/061320 WO2013178812A1 (en) 2012-05-31 2013-05-31 Risperidone or paliperidone implant formulation

Publications (2)

Publication Number Publication Date
KR20150016964A KR20150016964A (ko) 2015-02-13
KR101880716B1 true KR101880716B1 (ko) 2018-08-17

Family

ID=46147376

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035300A Active KR101880716B1 (ko) 2012-05-31 2013-05-31 리스페리돈 또는 팔리페리돈 임플란트 제형

Country Status (32)

Country Link
EP (2) EP2529756B1 (https=)
JP (1) JP6367795B2 (https=)
KR (1) KR101880716B1 (https=)
CN (1) CN104363923A (https=)
AU (1) AU2013269547B2 (https=)
BR (1) BR112014029209A2 (https=)
CA (1) CA2874765C (https=)
CL (1) CL2014003216A1 (https=)
CO (1) CO7160108A2 (https=)
CY (1) CY1124369T1 (https=)
DK (2) DK2529756T3 (https=)
EA (1) EA031819B1 (https=)
ES (1) ES2878112T3 (https=)
FI (1) FI2854858T3 (https=)
HR (2) HRP20260301T1 (https=)
IL (1) IL235849B (https=)
IN (1) IN2014DN10672A (https=)
LT (2) LT2529756T (https=)
MA (1) MA37664B1 (https=)
MX (1) MX374955B (https=)
MY (1) MY174999A (https=)
NZ (1) NZ703321A (https=)
PH (1) PH12014502667B1 (https=)
PL (2) PL2529756T3 (https=)
PT (2) PT2529756T (https=)
RS (1) RS62059B1 (https=)
SG (1) SG11201407961WA (https=)
SI (1) SI2529756T1 (https=)
SM (1) SMT202100448T1 (https=)
UA (1) UA119430C2 (https=)
WO (1) WO2013178812A1 (https=)
ZA (1) ZA201409299B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
LT2529756T (lt) * 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidono ir (arba) paliperidono implantų kompozicija
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104922085B (zh) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 一种利培酮植入剂及其制备方法
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
AU2023281232A1 (en) 2022-05-18 2024-10-24 Laboratorios Farmacéuticos Rovi, S.A. Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151355A1 (en) * 2010-05-31 2011-12-08 Laboratorios Farmacéuticos Rovi, S.A. Antipsychotic injectable depot composition
WO2011151356A2 (en) * 2010-05-31 2011-12-08 Laboratorios Farmacéuticos Rovi, S.A. Methods for the preparation of injectable depot compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2005007122A2 (en) * 2003-07-18 2005-01-27 Oakwood Laboratories, L.L.C. Polymer stabilization
JP2008509144A (ja) 2004-08-04 2008-03-27 アルザ・コーポレーシヨン 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法
JP5315336B2 (ja) 2007-04-19 2013-10-16 又欣 李 精神疾患治療用の新規化合物とその調剤及び使用
DK2167039T3 (en) * 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
WO2009015828A1 (en) 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
BRPI0821408A2 (pt) 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
LT2529756T (lt) * 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidono ir (arba) paliperidono implantų kompozicija

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151355A1 (en) * 2010-05-31 2011-12-08 Laboratorios Farmacéuticos Rovi, S.A. Antipsychotic injectable depot composition
WO2011151356A2 (en) * 2010-05-31 2011-12-08 Laboratorios Farmacéuticos Rovi, S.A. Methods for the preparation of injectable depot compositions

Also Published As

Publication number Publication date
CA2874765A1 (en) 2013-12-05
JP6367795B2 (ja) 2018-08-01
ZA201409299B (en) 2015-12-23
SI2529756T1 (sl) 2021-09-30
PH12014502667B1 (en) 2020-01-22
HRP20260301T1 (hr) 2026-04-10
SG11201407961WA (en) 2014-12-30
IN2014DN10672A (https=) 2015-08-28
BR112014029209A2 (pt) 2017-06-27
PT2529756T (pt) 2021-07-28
EA031819B1 (ru) 2019-02-28
HRP20211057T1 (hr) 2021-10-01
PH12014502667A1 (en) 2015-02-02
KR20150016964A (ko) 2015-02-13
CY1124369T1 (el) 2022-07-22
MX374955B (es) 2025-03-06
CN104363923A (zh) 2015-02-18
LT2529756T (lt) 2021-07-26
CL2014003216A1 (es) 2015-07-10
EP2529756A3 (en) 2013-08-07
EP2854858B1 (en) 2025-12-10
CO7160108A2 (es) 2015-01-15
EA201401346A1 (ru) 2015-04-30
RS62059B1 (sr) 2021-07-30
PL2854858T3 (pl) 2026-04-20
AU2013269547B2 (en) 2018-03-15
CA2874765C (en) 2020-06-02
AU2013269547A1 (en) 2015-01-22
DK2529756T3 (da) 2021-08-02
IL235849B (en) 2019-03-31
EP2529756B1 (en) 2021-05-19
MY174999A (en) 2020-06-01
EP2529756A2 (en) 2012-12-05
MA37664B1 (fr) 2016-11-30
WO2013178812A1 (en) 2013-12-05
NZ703321A (en) 2017-01-27
UA119430C2 (uk) 2019-06-25
SMT202100448T1 (it) 2021-09-14
PL2529756T3 (pl) 2021-11-15
EP2854858A1 (en) 2015-04-08
MX2014014483A (es) 2015-02-24
IL235849A0 (en) 2015-01-29
PT2854858T (pt) 2026-03-06
FI2854858T3 (fi) 2026-03-03
LT2854858T (lt) 2026-03-10
MA37664A1 (fr) 2016-03-31
ES2878112T3 (es) 2021-11-18
JP2015518036A (ja) 2015-06-25
DK2854858T3 (da) 2026-03-09

Similar Documents

Publication Publication Date Title
KR101880716B1 (ko) 리스페리돈 또는 팔리페리돈 임플란트 제형
KR101892496B1 (ko) 팔리페리돈 임플란트 제형
US12318478B2 (en) Risperidone or paliperidone implant formulation
US11013683B2 (en) Paliperidone implant formulation
JP5882993B2 (ja) 抗精神病薬デポ型注射用組成物
RS53205B (sr) Formulacija implantabilnog paliperidona
JP2024534540A (ja) 抗精神病性注入可能持続放出組成物
HK40006866A (en) Paliperidone implant formulation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170125

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171030

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20180423

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180716

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180717

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20210708

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20210708

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20220707

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20220707

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240704

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250703

Start annual number: 8

End annual number: 8